B. Braun Medical vice president Sam Amory said: “We are pleased to add the Streamline® bloodline to our dialysis product portfolio.
“Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog® hemodialysis machine and the Diacap® PRO dialyzer.”
The acquisition is subject to Federal Trade Commission approval and contingent upon the closing of the pending merger of NxStage with a subsidiary of Fresenius Medical Holdings, Inc. The B. Braun acquisition of the bloodlines business is expected to take place in 2018.
B. Braun Medical Inc. – a leader in renal therapies, infusion therapy and pain management – develops, manufactures, and markets innovative medical products and services to the healthcare industry.
The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its “Sharing Expertise®” philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
The B. Braun Group of Companies in the U.S. includes B. Braun, B. Braun Interventional Systems, Aesculap® and CAPS®. B. Braun’s U.S. headquarters is located in Bethlehem, Pennsylvania.
The B. Braun Group of Companies employs more than 61,000 employees in 64 countries throughout the world.
Source: Company Press Release
